{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/restless-legs-syndrome/background-information/causes/","result":{"pageContext":{"chapter":{"id":"f6fe6742-330a-5aea-8b52-b32fc2b3ab48","slug":"causes","fullItemName":"Causes","depth":2,"htmlHeader":"<!-- begin field e7027e94-1739-4e68-96ba-8138f9b36c04 --><h2>What causes it?</h2><!-- end field e7027e94-1739-4e68-96ba-8138f9b36c04 -->","summary":"","htmlStringContent":"<!-- begin item 4dee8886-8ea0-4880-aea2-38629f432142 --><!-- begin field 685a2a3c-4d41-494d-8176-b0da85929c05 --><ul><li><strong>In most people with restless legs syndrome (RLS) there is no apparent underlying cause </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/restless-legs-syndrome/references/\">Leschziner, 2012</a>]<strong>.</strong><ul><li>Dysfunction of the dopaminergic system is likely to play a part, but the cause of this dysfunction is not clear. Dopamine activity in the brain has a circadian rhythm that may explain the diurnal variation of the symptoms [<a class=\"bibliography-reference internal-reference\" href=\"/topics/restless-legs-syndrome/references/\">Nagandla, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/restless-legs-syndrome/references/\">Earley, 2014</a>].</li><li>Dysfunction of iron metabolism may be implicated, even in people who are not iron deficient. Iron is known to have a crucial role in dopamine metabolism. A widely held theory is that insufficient iron levels in the brain leads to a decrease in dopaminergic function that in turn leads to spinal hyperexcitability, which causes the symptoms of RLS [<a class=\"bibliography-reference internal-reference\" href=\"/topics/restless-legs-syndrome/references/\">Nagandla, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/restless-legs-syndrome/references/\">Earley, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/restless-legs-syndrome/references/\">Garcia-Borreguero, 2014</a>].</li><li>RLS can be familial and is thought to be most commonly inherited in an autosomal dominant pattern. Up to 50% of affected people have a family history of RLS [<a class=\"bibliography-reference internal-reference\" href=\"/topics/restless-legs-syndrome/references/\">BMJ Best Practice, 2019</a>]. However, several susceptibility loci have been identified and so inheritance patterns can also be more complex [<a class=\"bibliography-reference internal-reference\" href=\"/topics/restless-legs-syndrome/references/\">Garcia-Borreguero, 2017</a>].</li></ul></li><li><strong>RLS </strong><strong>is also associated with a number of comorbid conditions, most commonly:</strong><br><ul><li><strong>Pregnancy</strong> — RLS occurs in around 21% of pregnant women, most commonly in the third trimester [<a class=\"bibliography-reference internal-reference\" href=\"/topics/restless-legs-syndrome/references/\">Chen, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/restless-legs-syndrome/references/\">Darvishi, 2020</a>]. Women who have transient RLS during pregnancy have a four-fold increased risk of developing idiopathic RLS later in life [<a class=\"bibliography-reference internal-reference\" href=\"/topics/restless-legs-syndrome/references/\">Cesnik, 2010</a>].</li><li><strong>Iron deficiency</strong> — present in about 24% of people with RLS [<a class=\"bibliography-reference internal-reference\" href=\"/topics/restless-legs-syndrome/references/\">Allen, 2013</a>]. Most people with iron deficiency do not have RLS, but iron deficiency is thought to precipitate or exacerbate RLS in some people [<a class=\"bibliography-reference internal-reference\" href=\"/topics/restless-legs-syndrome/references/\">Leschziner, 2012</a>].</li><li><strong>Stage 5 chronic kidney disease</strong> — RLS occurs in about 20% of people undergoing renal dialysis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/restless-legs-syndrome/references/\">Gigli, 2004</a>].</li></ul></li><li><strong>A number of psychological and behavioural disorders have been associated with RLS in cross-sectional epidemiological studies, although there is no robust evidence of causality. These include:</strong><ul><li>Major depressive disorder.</li><li>Generalized anxiety disorder.</li><li>Panic disorder.</li><li>Attention-deficit hyperactivity disorder (ADHD).</li></ul></li><li><strong>Other conditions that have been associated with RLS (generally based on limited evidence) include:</strong><br><ul><li>A range of neurological conditions, including Parkinsonism, multiple sclerosis, polyneuropathies, acute spinal cord lesions, spinal stenosis, Charcot-Marie-Tooth disease, and lumbosacral radiculopathy.</li><li>Rheumatoid arthritis.</li><li>Diabetes.</li><li>Hypothyroidism.</li><li>Obesity.</li></ul></li><li><strong>Certain drugs/substances can precipitate or exacerbate RLS, including:</strong><ul><li>Antidepressants (including tricyclic antidepressants, selective serotonin re-uptake inhibitors, and serotonin noradrenaline re-uptake inhibitors).</li><li>Some antipsychotics and lithium.</li><li>Some antiepileptic drugs.</li><li>Antihistamines.</li><li>Dopamine receptor blocking agents, such as metoclopramide and prochlorperazine.</li><li>Beta-blockers.</li><li>Excessive intake of alcohol, caffeine, or chocolate.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/restless-legs-syndrome/references/\">Leschziner, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/restless-legs-syndrome/references/\">Ohayon, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/restless-legs-syndrome/references/\">Garcia-Borreguero, 2017</a>]</p><!-- end field 685a2a3c-4d41-494d-8176-b0da85929c05 --><!-- end item 4dee8886-8ea0-4880-aea2-38629f432142 -->","topic":{"id":"ce2c49b0-9c88-5bbe-b742-179c3a41de7d","topicId":"8560b6b4-74c4-48fb-99b2-1738f7bdfc1c","topicName":"Restless legs syndrome","slug":"restless-legs-syndrome","lastRevised":"Last revised in November 2020","chapters":[{"id":"0c5685ed-e78f-5c68-8983-83a722c74100","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"e6a7ab99-3bce-5334-8352-694d31ef5cc0","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"461085e4-b723-57af-8f1a-16da6b5276cd","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"8a4d8c25-f2fc-5706-989b-f6210f6e1fb8","slug":"changes","fullItemName":"Changes"},{"id":"08d30779-72aa-5609-89bb-35fa111203a1","slug":"update","fullItemName":"Update"}]},{"id":"8544bde0-46f9-502a-aec7-2a5a2d449009","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"c04c9edd-95d7-5e3f-94ea-5c7ecd6205a8","slug":"goals","fullItemName":"Goals"},{"id":"4d33d470-bfd2-518f-aebb-b9e86daa02ab","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"ab4dd298-08f9-5497-81cd-0ab7e978b675","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"8d907e60-5b96-5b39-a188-b481acc2935a","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"330f64fa-36dd-5bd9-847c-b379cdd7b437","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"9a4d2e02-acae-5411-92f3-bca31ce98b25","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"877ed575-950a-5933-ae1f-abcee48927b8","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"623e0c19-8a9e-5892-b3f3-a72ab9d617ce","slug":"definition","fullItemName":"Definition"},{"id":"f6fe6742-330a-5aea-8b52-b32fc2b3ab48","slug":"causes","fullItemName":"Causes"},{"id":"7a8e05a8-1db9-5aac-9b56-c5be8e7eb9d6","slug":"prevalence","fullItemName":"Prevalence"},{"id":"86293e20-8427-58da-8512-93f22162d764","slug":"prognosis","fullItemName":"Prognosis"},{"id":"043ee2a1-37c5-5b2f-8d10-0a9d2d41abe0","slug":"complications","fullItemName":"Complications"}]},{"id":"0ef4212f-c56f-508b-897c-741bceff55bb","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"6836b996-4eee-5e2a-a99b-84973696e8e3","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"5ccc9458-1b9d-5fa7-a565-2b00a539b9bd","slug":"assessment","fullItemName":"Assessment"},{"id":"729e434c-5849-59fb-b3ca-e7a86f26a8d6","slug":"investigations","fullItemName":"Investigations"},{"id":"0ce4b1b3-2e3a-5901-8e9c-981cea4198d7","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"7a12e175-49ce-5c68-9c8f-756159646a3f","fullItemName":"Management","slug":"management","subChapters":[{"id":"33ccae89-80e7-572a-b148-a81c781d0956","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"9b2fd470-be46-5a93-9f1a-502f0a8434dc","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"ae3af6c6-eb78-5674-a94f-f5f087e5f812","slug":"pramipexole","fullItemName":"Pramipexole"},{"id":"1664194f-800a-54c6-bd79-106678653aaa","slug":"ropinirole","fullItemName":"Ropinirole"},{"id":"1a0b2fc3-18c3-51a9-968c-88bb51f2637f","slug":"rotigotine","fullItemName":"Rotigotine"},{"id":"87f55f71-dd3d-5e97-9c88-5fe3a78503db","slug":"pregabalin","fullItemName":"Pregabalin"},{"id":"a931371b-564c-5833-b5b4-d21ad3f1a361","slug":"gabapentin","fullItemName":"Gabapentin"},{"id":"6590cad9-132e-548c-b7ad-bf4375ef2caf","slug":"codeine","fullItemName":"Codeine"},{"id":"70676cc9-d1a4-5639-a227-62e452e13b2b","slug":"benzodiazepines-z-drugs","fullItemName":"Benzodiazepines and Z-drugs"},{"id":"fe9dc2de-9fbe-527f-b34b-446254f3d127","slug":"augmentation","fullItemName":"Augmentation"},{"id":"2203998a-e9f3-59c3-9132-50418bf47566","slug":"loss-of-efficacy","fullItemName":"Loss of efficacy"},{"id":"7d279d8d-8d6c-5c7d-8597-6ee343a7a574","slug":"impulse-control-disorders","fullItemName":"Impulse control disorders"}]},{"id":"0fadb6b8-91c2-57be-8c1d-2d3e31da6d60","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"afa91ee5-1f42-5cc6-b9ec-6ef16749457d","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"baf472ab-f0f9-518a-8310-81583fd7d905","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"9d31c719-7426-52cb-8343-b11a7bb8b5b3","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"a915b18c-93a0-5269-8ff1-021677ba9dd3","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"6e85726f-b5ea-5c2c-a886-f74ab46fbc6b","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"8ac2285b-b086-5b54-98d6-0ec8c43f05c2","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"8a058ec2-b2e0-5618-b51f-27102b964d76","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"877ed575-950a-5933-ae1f-abcee48927b8","slug":"background-information","fullItemName":"Background information"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}